-
-
-
-
-
-
-
Prothena authorizes $100 million share repurchase program
-
-
-
-
-
-
-
Prothena Corp. (PRTA) Tops Q3 EPS by 4c
-
-
-
-
-
-
-
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
-
-
-
-
-
-
-
Prothena Corp. (PRTA) announces Phase 3 trial for Birtamimab did not meet endpoint
-
-
-
-
-
-
-
Prothena Corp. (PRTA) Misses Q4 EPS by 8c
-
-
-
-
-
-
-
Prothena Corp (PRTA) PT Lowered to $62 at Oppenheimer
-
-
-
-
-
-
-
Prothena Corp. (PRTA) Misses Q4 EPS by 8c
-
1,216,206 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

